Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.08 USD | 0.00% | -12.99% | +146.40% |
05-08 | Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study | CI |
04-16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+146.40% | 39.69M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- LEXX Stock
- News Lexaria Bioscience Corp.
- Lexaria Bioscience Set to File Investigational New Drug Application for Hypertension Trial Within 45 Days